Fintel reports that on July 14, 2025, BTIG upgraded their outlook for Synchrony Financial - Preferred Stock (NYSE:SYF.PRB) from Neutral to Buy. What is the Fund Sentiment? There are 39 funds or ...

Fintel reports that on July 14, 2025, BTIG downgraded their outlook for TechnipFMC (NYSE:FTI) from Buy to Neutral. Analyst ...

Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat ...

As of Monday, the S&P 500 has been trading above its 20-day moving average for 55 days. That's the longest stretch since ...

BTIG downgraded AFRM to "neutral" from "buy" Though shares of buy-now-pay-later name Affirm Holdings Inc (NASDAQ:AFRM) have ...

I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision ...

Brokerage firm BTIG LLC accused StoneX Group Inc., a rival brokerage and investment bank, of stealing its proprietary software code in what its lawyers describe as “one of the greatest financial ...

Billionaire Kerr Neilson has bought over $8 million worth of shares in Flutter Entertainment plc (NYSE:FLUT), representing ...

BTIG analyst Jeet Mukherjee initiated coverage of Arvinas (ARVN) with a Buy rating and $69 price target The company’s lead program, vepdegestrant, is a potent ER degrader for being developed for ...

BTIG says the road to reclassifying cannabis as a less dangerous substance remains murky, with the process likely getting bogged down for years by legal delays. Read more here.

BTIG sees increased stability for the medtech sector in 2024, helped by election year dynamics, as it makes its top stock picks for the coming year. Read more here.